The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
This paper provides a number of recommendations for expressing the behavioral semantics of a digital health enterprise. This includes the specification of policies, processes and services, with a particular focus on the RM-ODP enterprise and computational concerns. We believe that these behavioral aspects are needed to complement well developed expression of information semantics. The paper is motivated...
It has been ten years since the publication of our first paper reporting on the beginning of a new national e- health interoperability journey in Australia and the interoperability framework developed by National e-health Transition Authority (NEHTA) [1]. Many new technologies, standard efforts and architecture approaches have emerged since then. Many new lessons were also learned by different stakeholders...
This paper describes the experiences of Australia’s National E-Health Transition Authority in using the RM-ODP to address a number of interoperability challenges in Australian eHealth. The RM-ODP viewpoints provide the separation of concerns across a specification, allowing direct support of independent capability levels within an eHealth community. The RM-ODP provides precise architectural expression,...
Heading Obesity is linked with a range of other cardiovascular disease risk factors, including dyslipidaemia, insulin resistance, type 2 (non-insulin-dependent) diabetes mellitus and hypertension. Orlistat [‘Xenical’; Hoffmann-La Roche) is a novel non-systemically acting anti-obesity agent that inhibits gastrointestinal lipases and prevents the absorption of about one-third of dietary fats. Results from the orlistat phase III clinical research programme, presented at the International Congress on Vascular Disease Prevention [...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.